NO136198B - - Google Patents
Download PDFInfo
- Publication number
- NO136198B NO136198B NO3716/72A NO371672A NO136198B NO 136198 B NO136198 B NO 136198B NO 3716/72 A NO3716/72 A NO 3716/72A NO 371672 A NO371672 A NO 371672A NO 136198 B NO136198 B NO 136198B
- Authority
- NO
- Norway
- Prior art keywords
- methoxy
- solution
- eburnane
- carboxy
- apovincamine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- OZDNDGXASTWERN-CTNGQTDRSA-N Apovincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-CTNGQTDRSA-N 0.000 claims description 6
- 229950006936 apovincamine Drugs 0.000 claims description 6
- OZDNDGXASTWERN-UHFFFAOYSA-N apovincamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229960002726 vincamine Drugs 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VLFDXKBCNKXRBE-YTQUADARSA-N (+)-Isoeburnamine Natural products O[C@@H]1n2c3c(c4c2[C@H]2[C@@](CC)(C1)CCC[N+]2CC4)cccc3 VLFDXKBCNKXRBE-YTQUADARSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- HONLKDDLTAZVQV-NZSAHSFTSA-N Eburnamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@H]3[C@@]4(CC)C[C@@H](O)N5C2=C1 HONLKDDLTAZVQV-NZSAHSFTSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- -1 alkali metal methoxide Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- HONLKDDLTAZVQV-UHFFFAOYSA-N eburnamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)N5C2=C1 HONLKDDLTAZVQV-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
Description
Foreliggende oppfinnelse angår en analogifremgangsmåte ved fremstilling av den nye, terapeutisk aktive forbindelse, l6-carboxy-17-methoxy-eburnan med formelen: The present invention relates to an analogue method for the production of the new, therapeutically active compound, 16-carboxy-17-methoxy-eburnane with the formula:
og salter av denne forbindelse. and salts of this compound.
Det er allerede kjent at alkaloider av eburnamintypen som vincamin og dets derivater, kan anvendes i terapien som blodtrykk-senkende og cerebral vasodilaterende midler (L. Szporny, K. Szåsz: It is already known that alkaloids of the eburnamine type, such as vincamine and its derivatives, can be used in therapy as blood pressure-lowering and cerebral vasodilatory agents (L. Szporny, K. Szåsz:
Arch. Exp. Path. Pharmacol. 236, 296 (1957)). Arch. Exp. Path. Pharmacol. 236, 296 (1957)).
Det har nu vist seg at det nye alkaloid, 16-carboxy-17-methoxy-eburnan med formel (I) og dets salter har verdifulle farmakologiske egenskaper. It has now been shown that the new alkaloid, 16-carboxy-17-methoxy-eburnane of formula (I) and its salts have valuable pharmacological properties.
De farmakologiske egenskaper av den nye fremgangsmåteforbind-else er beslektet med dem for vincamin, en forbindelse anvendt i terapien med gode resultater. De relative verdier er oppsummert i tabell 1. LD ^-verdiene ble bestemt på hvite mus ved intravenøs administrasjon (Miller L. C, Tainter M. L.: Proe. Soc. Exp. Biol. Med. 57, 261 (1944))- LD-verdiene er i tabell 1 angitt i relasjon til vincamin, dvs. jo høyere den relative verdi, desto gunstigere er toksisiteten av angjeldende forbindelse. The pharmacological properties of the new process compound are related to those of vincamine, a compound used in therapy with good results. The relative values are summarized in Table 1. The LD ^ values were determined in white mice by intravenous administration (Miller L. C, Tainter M. L.: Proe. Soc. Exp. Biol. Med. 57, 261 (1944))- LD- the values are given in table 1 in relation to vincamine, i.e. the higher the relative value, the more favorable the toxicity of the compound in question.
Ved undersøkelse av virkningene utøvet på blodtrykk og cerebral strømning, ble intravenøse doser på 4 mg/dyr, såvel som intra-arteriale doser på 1 mg/dyr av de undersøkte forbindelser anvendt. In examining the effects exerted on blood pressure and cerebral flow, intravenous doses of 4 mg/animal, as well as intra-arterial doses of 1 mg/animal of the investigated compounds were used.
Forsøkene ble utført på hunder. Undersøkelsen av virkningen av forbindelsene utøvet på cerebral sirkulasjon, cerebral strømning (arteria carotis interna) og den vasculære motstand ble registrert hhv. beregnet. Forbindelsene ble administrert ad intravenøs og intraarterial vei. The experiments were carried out on dogs. The examination of the effect of the compounds exerted on cerebral circulation, cerebral flow (arteria carotis interna) and the vascular resistance was recorded respectively. calculated. The compounds were administered intravenously and intraarterially.
Blant de relative verdier angitt i tabell 1, representerer de største den høyeste nedsettelse eller økning. Among the relative values indicated in Table 1, the largest represent the highest reduction or increase.
Av disse data fremgår det at l6-carboxy-l7-methoxy-eburnan er ca. 3 ganger mindre toksisk enn vincamin, og effektivt øker den cerebrale strøm. From these data it appears that l6-carboxy-l7-methoxy-eburnane is approx. 3 times less toxic than vincamine, and effectively increases cerebral current.
Det nye alkaloid med formel (I) fremstilles ved å omsette apovincamin med et alkalimetallalkoholat. The new alkaloid of formula (I) is prepared by reacting apovincamine with an alkali metal alcoholate.
En detaljert omtale av foreliggende fremgangsmåte er gitt nedenfor. A detailed description of the present method is given below.
Apovincamin oppløses i et oppløsningsmiddel, fortrinnsvis en alkohol, oppløsningen oppvarmes til kokning, og en oppløsning av alkalimetallmethoxyd tilsettes dråpevis til reaksjonsbland-ingen. Reaksjonens forløp følges ved tynnskiktskromatografi. Blandingen kokes inntil flekken som er karakteristisk for apovincamin, forsvinner, derefter avkjøles oppløsningen og nøytraliseres til pH 7,0 med en sterk syre, fortrinnsvis med konsentrert saltsyre. Oppløsningen inndampes til tørrhet, og det tørre residuum oppløses i et klorert hydrocarbon, fortrinnsvis i methylenklorid. Den erholdte oppløsning filtreres, og filtratet inndampes til tørrhet under nedsatt trykk. Det tørre residuum oppløses i ethanol og krystalliseres. Apovincamine is dissolved in a solvent, preferably an alcohol, the solution is heated to boiling, and a solution of alkali metal methoxide is added dropwise to the reaction mixture. The progress of the reaction is followed by thin-layer chromatography. The mixture is boiled until the stain characteristic of apovincamine disappears, then the solution is cooled and neutralized to pH 7.0 with a strong acid, preferably with concentrated hydrochloric acid. The solution is evaporated to dryness, and the dry residue is dissolved in a chlorinated hydrocarbon, preferably in methylene chloride. The solution obtained is filtered, and the filtrate is evaporated to dryness under reduced pressure. The dry residue is dissolved in ethanol and crystallized.
Det nye, terapeutisk aktive l6-carboxy-l7-methoxy-eburnan som fremstilles ifølge oppfinnelsen, kan anvendes i terapien i form av farmasøytiske produkter. Slike farma-søytiske produkter, egnet for enteral, parenteral eller topisk applikasjon, inneholder det aktive middel sammen med organiske eller mineralske, faste eller flytende farmasøytisk godtagbare bærere. The new, therapeutically active 16-carboxy-17-methoxy-eburnane produced according to the invention can be used in therapy in the form of pharmaceutical products. Such pharmaceutical products, suitable for enteral, parenteral or topical application, contain the active agent together with organic or mineral, solid or liquid pharmaceutically acceptable carriers.
Fremgangsmåten ifølge oppfinnelsen vil bli ytterligere The method according to the invention will be further
belyst ved hjelp av det følgende eksempel. illustrated using the following example.
Eksempel 1 Example 1
l6- carboxy- 17- methoxy- eburnan 16-carboxy-17-methoxy-eburnane
0,14 g (0,006 mol) metallisk natrium oppløses i 100 ml vannfri methanol, og 1 g (0,0029 mol) apovincamin oppløses i den erholdte methanoliske natriummethoxydoppløsning. Reaksjonsblandingen kokes under tilbakeløp i 6 timer, og forløpet av reaksjonen følges ved skiktkromatografi. Flekken som er karakteristisk for apovincamin, forsvinner gradvis, og samtidig kommer en ny flekk tilsyne i kromatogrammet. Hvis overføringen ikke er fullstendig ved utløpet av 6 timer, tilsettes en natriummethoxydoppløsning fremstilt fra 0,014 g (0,0006 mol) metallisk natrium og 20 ml vannfri methanol til blandingen, og kokingen fortsettes i ytterligere 1 time. 0.14 g (0.006 mol) of metallic sodium is dissolved in 100 ml of anhydrous methanol, and 1 g (0.0029 mol) of apovincamine is dissolved in the methanolic sodium methoxy solution obtained. The reaction mixture is boiled under reflux for 6 hours, and the course of the reaction is followed by layer chromatography. The spot characteristic of apovincamine gradually disappears, and at the same time a new spot appears in the chromatogram. If the transfer is not complete at the end of 6 hours, a sodium methoxy solution prepared from 0.014 g (0.0006 mol) of metallic sodium and 20 ml of anhydrous methanol is added to the mixture and the boiling is continued for another 1 hour.
Oppløsningen avkjøles til 20°C og nøytraliseres til pH 7,0 med konsentrert saltsyre. Den erholdte oppløsning inndampes til tørrhet under nedsatt trykk. Det tørre residuum oppløses i 50 ml methylenklorid, og oppløsningen hensettes ved o - 2°C i 4 - 5 timer. The solution is cooled to 20°C and neutralized to pH 7.0 with concentrated hydrochloric acid. The resulting solution is evaporated to dryness under reduced pressure. The dry residue is dissolved in 50 ml of methylene chloride, and the solution is left at o - 2°C for 4 - 5 hours.
De utskilte krystaller av natriumklorid frafiltreres, filtratet inndampes til tørrhet, og det tørre residuum oppløses i 20 ml vannfri ethanol. Produktet krystalliseres ved O - 2°C. The separated crystals of sodium chloride are filtered off, the filtrate is evaporated to dryness, and the dry residue is dissolved in 20 ml of anhydrous ethanol. The product crystallizes at 0 - 2°C.
0,78 9 (79%) l6-carboxy-17-methoxy-eburnan fåes. På basis av tynnskiktskromatografi dannes et ensartet produkt som smelter ved 264°C 0.78 9 (79%) of 16-carboxy-17-methoxy-eburnane is obtained. On the basis of thin-layer chromatography, a uniform product is formed which melts at 264°C
Analyse: Analysis:
Strukturen av produktet ble identifisert ved dets infrarøde spekt rum. The structure of the product was identified by its infrared spectrum.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO761366A NO761366L (en) | 1971-11-03 | 1976-04-22 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HURI455A HU166474B (en) | 1971-11-03 | 1971-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO136198B true NO136198B (en) | 1977-04-25 |
NO136198C NO136198C (en) | 1977-08-03 |
Family
ID=11000881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO3716/72A NO136198C (en) | 1971-11-03 | 1972-10-17 | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 16-CARBOXY-17-METHOXY-EBURNAN. |
Country Status (23)
Country | Link |
---|---|
JP (1) | JPS515400B2 (en) |
AR (1) | AR196498A1 (en) |
AT (2) | AT328624B (en) |
AU (1) | AU470084B2 (en) |
BE (1) | BE790842A (en) |
BG (2) | BG20601A3 (en) |
CA (1) | CA982585A (en) |
CH (2) | CH577504A5 (en) |
DD (1) | DD101405A5 (en) |
DE (1) | DE2253778A1 (en) |
EG (1) | EG10720A (en) |
ES (1) | ES408184A1 (en) |
FR (1) | FR2158371B1 (en) |
GB (1) | GB1402085A (en) |
HU (1) | HU166474B (en) |
IL (1) | IL40623A (en) |
NL (1) | NL7214768A (en) |
NO (1) | NO136198C (en) |
PL (1) | PL71069B1 (en) |
RO (2) | RO63053A (en) |
SE (1) | SE7508516L (en) |
SU (1) | SU438183A3 (en) |
ZA (1) | ZA727382B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU532001B2 (en) * | 1978-11-20 | 1983-09-15 | Sumitomo Chemical Company, Limited | Polycyclic indole derivatives |
US4316028A (en) * | 1978-11-20 | 1982-02-16 | Sumitomo Chemical Company, Limited | Process for producing eburnane derivatives |
HU187139B (en) * | 1982-06-30 | 1985-11-28 | Richter Gedeon Vegyeszet | Process for preparing new eburnan derivatives |
RU2762189C2 (en) * | 2016-08-04 | 2021-12-16 | Харбин Фармасьютикал Груп Ко., Лтд. Дженерал Фармасьютикал Фэктори | Salts and crystalline forms of diazabenzofluoranthene compounds |
-
1971
- 1971-11-03 HU HURI455A patent/HU166474B/hu unknown
-
1972
- 1972-10-16 CH CH1320575A patent/CH577504A5/xx not_active IP Right Cessation
- 1972-10-16 CA CA153,943A patent/CA982585A/en not_active Expired
- 1972-10-16 CH CH1510372A patent/CH586702A5/xx not_active IP Right Cessation
- 1972-10-17 ZA ZA727382A patent/ZA727382B/en unknown
- 1972-10-17 NO NO3716/72A patent/NO136198C/en unknown
- 1972-10-19 BG BG21668A patent/BG20601A3/xx unknown
- 1972-10-19 BG BG23693A patent/BG20379A3/xx unknown
- 1972-10-19 IL IL40623A patent/IL40623A/en unknown
- 1972-10-20 AU AU47984/72A patent/AU470084B2/en not_active Expired
- 1972-10-21 EG EG440/72A patent/EG10720A/en active
- 1972-10-25 AT AT978773*7A patent/AT328624B/en not_active IP Right Cessation
- 1972-10-25 AT AT910372A patent/AT318823B/en not_active IP Right Cessation
- 1972-10-31 FR FR7238529A patent/FR2158371B1/fr not_active Expired
- 1972-10-31 BE BE790842D patent/BE790842A/en unknown
- 1972-10-31 DD DD166591A patent/DD101405A5/xx unknown
- 1972-11-01 NL NL7214768A patent/NL7214768A/xx unknown
- 1972-11-01 JP JP47108965A patent/JPS515400B2/ja not_active Expired
- 1972-11-02 DE DE2253778A patent/DE2253778A1/en active Pending
- 1972-11-02 ES ES408184A patent/ES408184A1/en not_active Expired
- 1972-11-02 SU SU1843735A patent/SU438183A3/en active
- 1972-11-02 GB GB810074A patent/GB1402085A/en not_active Expired
- 1972-11-02 AR AR244942A patent/AR196498A1/en active
- 1972-11-02 PL PL1972158592A patent/PL71069B1/en unknown
- 1972-11-03 RO RO7200080514A patent/RO63053A/en unknown
- 1972-11-03 RO RO72721A patent/RO62345A/ro unknown
-
1975
- 1975-07-25 SE SE7508516A patent/SE7508516L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA982585A (en) | 1976-01-27 |
CH586702A5 (en) | 1977-04-15 |
BE790842A (en) | 1973-02-15 |
JPS515400B2 (en) | 1976-02-19 |
DD101405A5 (en) | 1973-11-05 |
AT318823B (en) | 1974-11-25 |
GB1402085A (en) | 1975-08-06 |
EG10720A (en) | 1976-07-31 |
FR2158371B1 (en) | 1975-08-08 |
ZA727382B (en) | 1973-06-27 |
RO62345A (en) | 1977-08-15 |
DE2253778A1 (en) | 1973-05-10 |
JPS4852800A (en) | 1973-07-24 |
RO63053A (en) | 1978-05-15 |
CH577504A5 (en) | 1976-07-15 |
HU166474B (en) | 1975-03-28 |
BG20379A3 (en) | 1975-11-05 |
NL7214768A (en) | 1973-05-07 |
ATA978773A (en) | 1975-06-15 |
NO136198C (en) | 1977-08-03 |
AU470084B2 (en) | 1976-03-04 |
AR196498A1 (en) | 1974-02-06 |
PL71069B1 (en) | 1974-04-30 |
BG20601A3 (en) | 1975-12-05 |
AT328624B (en) | 1976-03-25 |
IL40623A0 (en) | 1972-12-29 |
IL40623A (en) | 1975-12-31 |
ES408184A1 (en) | 1975-11-01 |
SE7508516L (en) | 1975-07-25 |
SU438183A3 (en) | 1974-07-30 |
AU4798472A (en) | 1974-04-26 |
FR2158371A1 (en) | 1973-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220098188A1 (en) | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors | |
JPS6299395A (en) | 2-alkinyladenosine and antihypertensive | |
AU2015269598B2 (en) | Novel quinoline derivatives and their use in neurodegenerative diseases | |
JP2021532077A (en) | A dimeric immunomodulatory compound that opposes the cereblon mechanism | |
JPH024235B2 (en) | ||
NO136198B (en) | ||
JPS58159492A (en) | Cholinantein derivative, manufacture and use | |
US3993781A (en) | 1,6-Dibromo-1,6-dideoxy-dulcitol and pharmaceutical compositions containing same | |
KR850000843B1 (en) | Process for preparing pyrrolidine derivatives | |
EP0313935B1 (en) | Enolethers of 6-chloro-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno(2,3-e)-1,2-thiazin-3-carboxylic acid amide-1,1-dioxide, a process for their preparation and their use | |
JPH05504146A (en) | Cycloalkyl-substituted glutaramide antihypertensive agent | |
CN106674245B (en) | The preparation of glucopyranosyl derivatives and application pharmaceutically | |
WO2021023512A1 (en) | Bifunctional compound and its use in immunotherapy | |
US3751408A (en) | Imidazole-ribosyl cyclophosphate compounds and therapeutic compositions | |
US4224327A (en) | 4-Pyrimidyl sulfides for the treatment of gastric ulcers | |
JPS6054960B2 (en) | Anti-inflammatory septacidin analogs | |
US4126616A (en) | N-propylnorapomorphine diesters | |
US2721203A (en) | Chloral nicotinamide and method for preparing the same | |
US3971798A (en) | Pyridine derivative, processes of preparation and pharmaceutical compositions | |
NO761366L (en) | ||
DE2722399A1 (en) | ANTI-INFLAMMATORY PRODUCTS, METHODS FOR ITS MANUFACTURING AND MEDICINAL PRODUCTS MANUFACTURED THEREOF | |
US20220332750A1 (en) | Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof | |
SU598892A1 (en) | Beta-(n,n-diethylamino) ethylamide 5-n-butyl-2-pyridinecarboxylic acid hydrochloride possessing antiarrhythmic effect | |
KR850000844B1 (en) | Process for preparing pyrrolidine derivatives | |
JPS634557B2 (en) |